

Aligos Therapeutics, Inc. (ALGS)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001799448

Aligos Therapeutics, Inc.		
ALGS; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$88.5M	
Standard universe	inside revenue above \$1M and assets above \$10M	
Warnings	short runway, thin data, distress not computable: dilution, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Mar 5, 2026 218 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026	
Last close	\$5.46 2026-10-08; market equity \$34.1M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARS-CoV-2, SARS-CoV, MERS-CoV, and other related infections). The Aligos team has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases, resulting in three potential best-in-class drug candidates.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 98.9						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		73.5%	(6.6%)	98.9	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 71.1						
Twelve-month failure probability		1.47%	0.07%	90.7	248	2026-06-30
Altman Z double-prime		(24.15)	(0.31)	76.6	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		3.90x	2.96x	46.2	839	2025-12-31
Growth and financing, sleeve percentile 76.8						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(15.5%)	2.1%	76.8	704	2025-12-31
Net share issuance, one year		not computable	2.5%			two annual share counts are required; found 1

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.9 months
Thin data	5 of 14 grade factors are computable; minimum is 7
Distress	CHS probability 1.467351%; universe top-decile threshold 1.068854%

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(40.2%)	8.0%	18
Distance from 52-week high	(60.1%)	(31.4%)	18
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(244.2%)	(1.0%)	3
Book value to price	0.96	0.28	86
Sales to price	0.07	0.31	20
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.73)	(0.14)	18

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$30.4M
Operating cash flow, four quarters	-\$94.2M
Months of runway	3.9
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$344,146

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$24.2M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$82.5M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
3	assets	us-gaap:Assets	\$88.5M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
4	assets	us-gaap:Assets	\$70.1M	2024-12-31	2026-03-05	10-K	0001193125-26-092614
5	current assets	us-gaap:AssetsCurrent	\$82.9M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
6	current liabilities	us-gaap:LiabilitiesCurrent	\$21.2M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$642.2M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
8	operating income	us-gaap:OperatingIncomeLoss	-\$88.0M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
9	book equity	us-gaap:StockholdersEquity	\$53.5M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
10	liabilities	us-gaap:Liabilities	\$35.0M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.2M	2025-12-31	2026-03-05	10-K	0001193125-26-092614
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.6M	2024-12-31	2026-03-05	10-K	0001193125-26-092614
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$6.2M	2023-12-31	2025-03-10	10-K	0000950170-25-035929
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2022-12-31	2023-03-09	10-K	0000950170-23-007033
15	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$80.7M	2024-12-31	2026-03-05	10-K	0001193125-26-092614
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$130,000	2024-12-31	2025-03-10	10-K	0000950170-25-035929
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$79.0M	2023-12-31	2025-03-10	10-K	0000950170-25-035929
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$19,000	2023-12-31	2025-03-10	10-K	0000950170-25-035929
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$79.4M	2022-12-31	2024-03-12	10-K	0000950170-24-029953
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$943,000	2022-12-31	2024-03-12	10-K	0000950170-24-029953
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$115.7M	2021-12-31	2023-03-09	10-K	0000950170-23-007033
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$892,000	2021-12-31	2023-03-09	10-K	0000950170-23-007033
23	depreciation amortization	us-gaap:Depreciation	\$1.0M	2024-12-31	2026-03-05	10-K	0001193125-26-092614
24	operating income	us-gaap:OperatingIncomeLoss	-\$89.2M	2024-12-31	2026-03-05	10-K	0001193125-26-092614
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsIncludin	-\$180.9M	2025-12-31	2026-03-05	10-K	0001193125-26-092614

26	income tax	us-gaap:IncomeTaxExpenseBenefit	\$331,000	2024-12-31	2026-03-05	10-K	0001193125-26-092614
27	current assets	us-gaap:AssetsCurrent	\$62.1M	2024-12-31	2026-03-05	10-K	0001193125-26-092614
28	current liabilities	us-gaap:LiabilitiesCurrent	\$21.7M	2024-12-31	2026-03-05	10-K	0001193125-26-092614
29	current assets	us-gaap:AssetsCurrent	\$141.1M	2023-12-31	2025-03-10	10-K	0000950170-25-035929
30	current liabilities	us-gaap:LiabilitiesCurrent	\$23.9M	2023-12-31	2025-03-10	10-K	0000950170-25-035929
31	assets	us-gaap:Assets	\$151.5M	2023-12-31	2025-03-10	10-K	0000950170-25-035929
32	assets	us-gaap:Assets	\$146.7M	2022-12-31	2024-03-12	10-K	0000950170-24-029953
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	38,143,228	2021-03-18	2021-03-23	10-K	0001564590-21-014872